PEN241220P370000
- 0.00
- 0.000.00%
Penumbra Newsroom
Penumbra Is Maintained at Buy by Canaccord Genuity
CCORF Maintains Penumbra(PEN.US) With Buy Rating, Raises Target Price to $323
Express News | Penumbra Inc : Canaccord Genuity Raises Target Price to $323 From $260
Penumbra's (NYSE:PEN) Investors Will Be Pleased With Their Notable 49% Return Over the Last Five Years
Why Penumbra (PEN) Is a Top Growth Stock for the Long-Term
TMO Stock to Gain From the New Additions to CTS Portfolio of Products
Will HAE Stock Gain Following Sell-Off of Whole Blood Assets to GVS?
Reasons to Retain EYE Stock in Your Portfolio for Now
Insider Sale: EVP of $PEN (PEN) Sells 281 Shares
Penumbra Management to Meet With BTIG
Penumbra Price Target Raised to $240 From $210 at Morgan Stanley
(PEN) - Analyzing Penumbra's Short Interest
Why Is Penumbra (PEN) Up 6.7% Since Last Earnings Report?
Leerink Partners Sticks to Their Buy Rating for Penumbra (PEN)
ABT Stock Benefits From First Patient Procedures With TAVI System
Penumbra Is Maintained at Buy by BTIG
International Expansion Supports BSX Stock Amid Macroeconomic Woes
BTIG Maintains Penumbra(PEN.US) With Buy Rating, Raises Target Price to $270
Cautious Hold Recommendation Amid Uncertainty Following FDA Clearance of Penumbra's Element Vascular Access System
Penumbra, Inc. (PEN): Innovating in Thrombectomy and Embolization With New FDA-Approved Technologies